{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T11:31:34Z","timestamp":1782646294863,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100020732","name":"innovative research team of high-level local universities in Shanghai","doi-asserted-by":"crossref","award":["SHSMUZDCX20211901"],"award-info":[{"award-number":["SHSMUZDCX20211901"]}],"id":[{"id":"10.13039\/100020732","id-type":"DOI","asserted-by":"crossref"}]},{"name":"New Quality Clinical Specialties of High-end Medical Disciplinary Construction in Pudong New Area","award":["2024-PWXZ-16"],"award-info":[{"award-number":["2024-PWXZ-16"]}]},{"name":"Interdisciplinary Program of Shanghai Jiao Tong University","award":["YG2023LC04"],"award-info":[{"award-number":["YG2023LC04"]}]},{"name":"Shanghai \u201cRising Stars of Medical Talents\u201d Youth Development Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s13760-025-02853-5","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T03:18:07Z","timestamp":1754277487000},"page":"1327-1334","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Influencing factors and clinical value of anti-aquaporin-4 antibody in cerebrospinal fluid: a study of 82 patients with neuromyelitis optica spectrum disorder"],"prefix":"10.1007","volume":"125","author":[{"given":"Jing","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiajun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangtai","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"issue":"2","key":"2853_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","volume":"96","author":"V Papp","year":"2021","unstructured":"Papp V et al (2021) Worldwide incidence and prevalence of neuromyelitis optica: A systematic review. Neurology 96(2):59\u201377","journal-title":"Neurology"},{"key":"2853_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.msard.2017.12.012","volume":"20","author":"P Beauchemin","year":"2018","unstructured":"Beauchemin P et al (2018) Paraneoplastic neuromyelitis Optica spectrum disorder: A single center cohort description with two cases of histological validation. Mult Scler Relat Disord 20:37\u201342","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"2853_CR3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon VA et al (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202(4):473\u2013477","journal-title":"J Exp Med"},{"issue":"9","key":"2853_CR4","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM et al (2007) The spectrum of neuromyelitis Optica. Lancet Neurol 6(9):805\u2013815","journal-title":"Lancet Neurol"},{"issue":"2","key":"2853_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM et al (2015) International consensus diagnostic criteria for neuromyelitis Optica spectrum disorders. Neurology 85(2):177\u2013189","journal-title":"Neurology"},{"issue":"1","key":"2853_CR6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","volume":"18","author":"E Carnero Contentti","year":"2021","unstructured":"Carnero Contentti E, Correale J (2021) Neuromyelitis Optica spectrum disorders: from pathophysiology to therapeutic strategies. J Neuroinflammation 18(1):208","journal-title":"J Neuroinflammation"},{"key":"2853_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1742-2094-7-52","volume":"7","author":"S Jarius","year":"2010","unstructured":"Jarius S et al (2010) Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis Optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation 7:52","journal-title":"J Neuroinflammation"},{"issue":"1","key":"2853_CR8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1212\/WNL.0000000000012175","volume":"97","author":"T Akaishi","year":"2021","unstructured":"Akaishi T et al (2021) Difference in the source of Anti-AQP4-IgG and Anti-MOG-IgG antibodies in CSF in patients with neuromyelitis Optica spectrum disorder. Neurology 97(1):e1\u2013e12","journal-title":"Neurology"},{"issue":"3","key":"2853_CR9","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1212\/NXI.0000000000000231","volume":"3","author":"M Majed","year":"2016","unstructured":"Majed M et al (2016) Clinical utility of testing AQP4-IgG in CSF: guidance for physicians. Neurol Neuroimmunol Neuroinflamm 3(3):e231","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1\u20132","key":"2853_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","volume":"306","author":"S Jarius","year":"2011","unstructured":"Jarius S et al (2011) Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 306(1\u20132):82\u201390","journal-title":"J Neurol Sci"},{"issue":"4","key":"2853_CR11","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00415-018-8771-5","volume":"265","author":"P Cabre","year":"2018","unstructured":"Cabre P et al (2018) Treatment of neuromyelitis Optica with rituximab: a 2-year prospective multicenter study. J Neurol 265(4):917\u2013925","journal-title":"J Neurol"},{"issue":"4","key":"2853_CR12","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","volume":"19","author":"M Tahara","year":"2020","unstructured":"Tahara M et al (2020) Safety and efficacy of rituximab in neuromyelitis Optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 19(4):298\u2013306","journal-title":"Lancet Neurol"},{"issue":"7","key":"2853_CR13","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.jocn.2010.12.011","volume":"18","author":"I Nakashima","year":"2011","unstructured":"Nakashima I et al (2011) Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J Clin Neurosci 18(7):997\u2013998","journal-title":"J Clin Neurosci"},{"issue":"7","key":"2853_CR14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","volume":"17","author":"MT Cencioni","year":"2021","unstructured":"Cencioni MT et al (2021) B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies. Nat Rev Neurol 17(7):399\u2013414","journal-title":"Nat Rev Neurol"},{"issue":"7900","key":"2853_CR15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","volume":"603","author":"TV Lanz","year":"2022","unstructured":"Lanz TV et al (2022) Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and glialcam. Nature 603(7900):321\u2013327","journal-title":"Nature"},{"key":"2853_CR16","doi-asserted-by":"crossref","unstructured":"Zhang C et al (2021) B-Cell compartmental features and molecular basis for therapy in autoimmune disease. Neurol Neuroimmunol Neuroinflamm 8(6):e1070","DOI":"10.1212\/NXI.0000000000001070"},{"issue":"03","key":"2853_CR17","first-page":"257","volume":"56","author":"CSo Neuroimmunology","year":"2023","unstructured":"Neuroimmunology CSo (2023) Expert consensus on the detection of antibodies associated with autoimmune diseases of the central nervous system. Chin J Neurol 56(03):257\u2013268","journal-title":"Chin J Neurol"},{"key":"2853_CR18","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.msard.2017.08.005","volume":"17","author":"RA Kessler","year":"2017","unstructured":"Kessler RA et al (2017) Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis Optica spectrum disorder: A multicenter cohort study. Mult Scler Relat Disord 17:198\u2013201","journal-title":"Mult Scler Relat Disord"},{"key":"2853_CR19","doi-asserted-by":"publisher","first-page":"577168","DOI":"10.1016\/j.jneuroim.2020.577168","volume":"340","author":"T Akaishi","year":"2020","unstructured":"Akaishi T et al (2020) Serum AQP4-IgG level is associated with the phenotype of the first attack in neuromyelitis Optica spectrum disorders. J Neuroimmunol 340:577168","journal-title":"J Neuroimmunol"},{"key":"2853_CR20","doi-asserted-by":"publisher","first-page":"116671","DOI":"10.1016\/j.jns.2020.116671","volume":"410","author":"T Akaishi","year":"2020","unstructured":"Akaishi T et al (2020) Repeated follow-up of AQP4-IgG titer by cell-based assay in neuromyelitis Optica spectrum disorders (NMOSD). J Neurol Sci 410:116671","journal-title":"J Neurol Sci"},{"issue":"1\u20132","key":"2853_CR21","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jneuroim.2011.01.007","volume":"234","author":"I Dujmovic","year":"2011","unstructured":"Dujmovic I et al (2011) Temporal dynamics of cerebrospinal fluid anti-aquaporin-4 antibodies in patients with neuromyelitis Optica spectrum disorders. J Neuroimmunol 234(1\u20132):124\u2013130","journal-title":"J Neuroimmunol"},{"key":"2853_CR22","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.msard.2018.10.114","volume":"27","author":"X You","year":"2019","unstructured":"You X et al (2019) Disruption of blood-brain barrier integrity associated with brain lesions in Chinese neuromyelitis Optica spectrum disorder patients. Mult Scler Relat Disord 27:254\u2013259","journal-title":"Mult Scler Relat Disord"},{"key":"2853_CR23","doi-asserted-by":"publisher","first-page":"577925","DOI":"10.1016\/j.jneuroim.2022.577925","volume":"370","author":"A Haramati","year":"2022","unstructured":"Haramati A et al (2022) IL-6 as a marker for NMOSD disease activity. J Neuroimmunol 370:577925","journal-title":"J Neuroimmunol"},{"key":"2853_CR24","doi-asserted-by":"crossref","unstructured":"Yong KP, Kim HJ (2022) Demystifying MOGAD and double seronegative NMOSD further with IL-6 Blockade. Neurol Neuroimmunol Neuroinflamm 9(1):e1110","DOI":"10.1212\/NXI.0000000000001110"},{"issue":"7","key":"2853_CR25","doi-asserted-by":"publisher","first-page":"103826","DOI":"10.1016\/j.autrev.2025.103826","volume":"24","author":"X Li","year":"2025","unstructured":"Li X, Zhao C (2025) Interleukin-6 in neuroimmunological disorders: pathophysiology and therapeutic advances with satralizumab. Autoimmun Rev 24(7):103826","journal-title":"Autoimmun Rev"},{"key":"2853_CR26","doi-asserted-by":"crossref","unstructured":"Kwon YN et al (2022) Myelin oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF: clinical implication of testing and association with disability. Neurol Neuroimmunol Neuroinflamm 9(1):e1095","DOI":"10.1212\/NXI.0000000000001095"},{"issue":"12","key":"2853_CR27","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1136\/jnnp-2024-333554","volume":"95","author":"G Greco","year":"2024","unstructured":"Greco G et al (2024) Clinical, prognostic and pathophysiological implications of MOG-IgG detection in the CSF: the importance of intrathecal MOG-IgG synthesis. J Neurol Neurosurg Psychiatry 95(12):1176\u20131186","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"2853_CR28","doi-asserted-by":"publisher","first-page":"e83036","DOI":"10.1371\/journal.pone.0083036","volume":"8","author":"N Chihara","year":"2013","unstructured":"Chihara N et al (2013) Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis Optica. PLoS ONE 8(12):e83036","journal-title":"PLoS ONE"},{"issue":"5","key":"2853_CR29","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ana.21802","volume":"66","author":"JL Bennett","year":"2009","unstructured":"Bennett JL et al (2009) Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis Optica. Ann Neurol 66(5):617\u2013629","journal-title":"Ann Neurol"},{"issue":"6","key":"2853_CR30","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/acn3.418","volume":"4","author":"MC Kowarik","year":"2017","unstructured":"Kowarik MC et al (2017) CNS Aquaporin-4-specific B cells connect with multiple B-cell compartments in neuromyelitis Optica spectrum disorder. Ann Clin Transl Neurol 4(6):369\u2013380","journal-title":"Ann Clin Transl Neurol"},{"key":"2853_CR31","doi-asserted-by":"publisher","first-page":"577500","DOI":"10.1016\/j.jneuroim.2021.577500","volume":"353","author":"N Uchida","year":"2021","unstructured":"Uchida N et al (2021) Systemic cellular immunity and neuroinflammation during acute flare-up in multiple sclerosis and neuromyelitis Optica spectrum disorder patients. J Neuroimmunol 353:577500","journal-title":"J Neuroimmunol"},{"issue":"5","key":"2853_CR32","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1007\/s00415-024-12180-z","volume":"271","author":"M Risi","year":"2024","unstructured":"Risi M et al (2024) MOG-IgG testing strategies in accordance with the 2023 MOGAD criteria: a clinical-laboratory assessment. J Neurol 271(5):2840\u20132843","journal-title":"J Neurol"},{"issue":"3","key":"2853_CR33","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/acn3.52310","volume":"12","author":"Y Said","year":"2025","unstructured":"Said Y et al (2025) Real-world clinical experience with serum MOG and AQP4 antibody testing by live versus fixed cell-based assay. Ann Clin Transl Neurol 12(3):556\u2013564","journal-title":"Ann Clin Transl Neurol"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-025-02853-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-025-02853-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-025-02853-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T10:42:56Z","timestamp":1760352176000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-025-02853-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2853"],"URL":"https:\/\/doi.org\/10.1007\/s13760-025-02853-5","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"27 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Ethics Committee of Renji Hospital (approval number: LY2023-086B).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all study participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}